Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Kowa Pharma, Eli Lilly PREVAIL US study of Livalo met primary endpoint of LDL-C reduction
Kowa Pharma, Eli Lilly PREVAIL US study of Livalo met primary endpoint of LDL-C reduction
Kowa Pharma, Eli Lilly PREVAIL US study of Livalo met primary endpoint of LDL-C reduction
Submitted by
admin
on June 3, 2012 - 12:35pm
Source:
Pharmabiz
News Tags:
Eli Lilly
Livalo
hypercholesterolemia
LDL cholesterol
Headline:
Kowa Pharma, Eli Lilly PREVAIL US study of Livalo met primary endpoint of LDL-C reduction
Do Not Allow Advertisers to Use My Personal information
